Abstract | PURPOSE:
Germ cell tumors (GCT) of the testis are highly curable, but those patients who are refractory to cisplatin (CDDP)-based combination chemotherapy have a poor prognosis. Therefore, identifying new alternatives for treatment remains a priority. Several studies support an important role for angiogenesis in GCTs, suggesting that antiangiogenic treatment might be a good alternative. Sunitinib is an oral multitarget tyrosine kinase receptor inhibitor with antiangiogenic and antitumor activities. In the present study, we evaluated the effect of sunitinib, CDDP, or the combination of both drugs using an orthotopic model of human testicular GCT. EXPERIMENTAL DESIGN: RESULTS: CONCLUSIONS: Taken together, these results suggest that sunitinib might be a new alternative for treatment of CDDP-refractory patients.
|
Authors | Wilmar Castillo-Avila, Josep Maria Piulats, Xavier Garcia Del Muro, August Vidal, Enric Condom, Oriol Casanovas, Josefina Mora, Josep Ramon Germà, Gabriel Capellà, Alberto Villanueva, Francesc Viñals |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 15
Issue 10
Pg. 3384-95
(May 15 2009)
ISSN: 1078-0432 [Print] United States |
PMID | 19417025
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Indoles
- Pyrroles
- Receptors, Platelet-Derived Growth Factor
- Receptors, Vascular Endothelial Growth Factor
- Cisplatin
- Sunitinib
|
Topics |
- Angiogenesis Inhibitors
(administration & dosage, pharmacology, therapeutic use)
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Apoptosis
(drug effects)
- Blotting, Western
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Cell Survival
(drug effects)
- Cisplatin
(administration & dosage, pharmacology)
- Drug Resistance, Neoplasm
- Drug Synergism
- Humans
- Indoles
(administration & dosage, pharmacology, therapeutic use)
- Male
- Mice
- Mice, Nude
- Neoplasms, Germ Cell and Embryonal
(blood supply, drug therapy, pathology)
- Neovascularization, Pathologic
(genetics, metabolism, prevention & control)
- Pyrroles
(administration & dosage, pharmacology, therapeutic use)
- Receptors, Platelet-Derived Growth Factor
(genetics, metabolism)
- Receptors, Vascular Endothelial Growth Factor
(genetics, metabolism)
- Reverse Transcriptase Polymerase Chain Reaction
- Sunitinib
- Survival Analysis
- Testicular Neoplasms
(blood supply, drug therapy, pathology)
- Tumor Burden
(drug effects)
- Xenograft Model Antitumor Assays
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|